Welcome to our dedicated page for Bausch + Lomb news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb stock.
Bausch + Lomb Corporation reports developments across its global eye health business, including vision care, surgical devices and ophthalmic pharmaceuticals. Recurring updates cover contact lenses and lens care products, eye vitamins and redness-relief drops, dry eye and prescription ophthalmology brands, intraocular lenses, vitrectomy cutters and the Stellaris Elite Vision Enhancement System.
Company news also includes financial results and guidance, scientific presentations, R&D pipeline discussions, FDA 510(k) clearances, European product launches and sustainability programs such as ONE by ONE Recycling. Product-specific coverage frequently references Biotrue, LUMIFY, XIIDRA, MIEBO, PreserVision, INFUSE, ULTRA ONE DAY, enVista and Bi-Blade technologies.
Bausch + Lomb (NYSE:BLCO) reported Q3 2025 revenue of $1.281B, up 7% reported and ~6% on a constant currency basis versus Q3 2024. Segment revenue: Vision Care $736M (+8%), Pharmaceuticals $330M (+8%), Surgical $215M (+4%).
GAAP net loss attributable was $28M; adjusted net income was $66M. Adjusted EBITDA (non-GAAP) and excluding acquired IPR&D were both $243M. Cash and equivalents were $332M. Updated full‑year 2025 guidance raised adjusted EBITDA ex‑IPR&D to $870M–$910M with revenue guidance unchanged at $5.05B–$5.15B.
Bausch + Lomb (NYSE/TSX: BLCO), a global eye health company, has scheduled two important investor events. The company will release its third-quarter 2025 financial results on Wednesday, October 29, 2025, at 8:00 a.m. ET, followed by a conference call and live webcast to discuss results and provide business updates.
Additionally, BLCO will host an investor day on November 13, 2025, where it plans to showcase its product pipeline, featuring potential game-changing innovations across all business units. The conference call will be accessible via webcast and phone, with replay available until November 12, 2025.
Bausch + Lomb (NYSE/TSX: BLCO) announced the publication of pivotal U.S. clinical trial results for their enVista Envy full range of vision intraocular lens (IOL) in the American Journal of Ophthalmology. The multicenter study involving 501 cataract patients demonstrated that the enVista Envy met all primary efficacy and safety endpoints.
The trial compared two groups: 332 patients received bilateral implantation of enVista Envy, while 169 patients received the enVista monofocal IOL. The Envy group showed superior results in intermediate and near visual acuity tests, while maintaining comparable distance vision and contrast sensitivity to the monofocal lens. The study reported no serious adverse events related to the lens and no secondary surgical interventions.
Bausch + Lomb (NYSE/TSX: BLCO) announced the publication of significant clinical study results for XIIDRA® in Clinical Ophthalmology. The investigator-initiated study demonstrated that XIIDRA effectively improved end-of-day eye dryness and discomfort in contact lens wearers.
Key findings showed that after 12 weeks of XIIDRA use, patients experienced a 61-point improvement in dryness and 59-point improvement in discomfort on a 100-point scale. The study revealed significant improvements in just two weeks, with comfortable contact lens wear time increasing from 6.5 to 9.1 hours. Notably, 90% of participants achieved clinically meaningful improvement in CLDEQ-8 scores after 12 weeks.
Bausch + Lomb (NYSE/TSX: BLCO) has launched ASANA™ gas permeable (GP) lenses in the United States, expanding its Specialty Vision Products portfolio. The comprehensive ASANA portfolio includes spherical, aspheric, toric, multifocal, reverse geometry and keratoconic lenses, designed to address complex vision challenges.
The ASANA lenses feature enhanced durability, maintaining shape throughout daily wear while resisting protein buildup. Eye care professionals receive support through consultant assistance for lens fittings, rapid manufacturing and shipping, and a 120-day EZ-Exchange™ Warranty Program with unlimited lens remakes. The lenses are custom-made exclusively with Boston® materials and are particularly beneficial for patients with high corneal astigmatism, severe refractive errors, keratoconus, and post-surgical vision correction needs.
Bausch + Lomb (NYSE/TSX: BLCO) announced changes to its Board of Directors following the termination of the Amended and Restated Director Appointment and Nomination Agreement with Carl C. Icahn and his affiliates. The agreement ended after the Icahn group's net long position in Bausch Health Companies Inc. fell below the required threshold.
As a result, Brett M. Icahn and Gary Hu have resigned from the Bausch + Lomb Board of Directors. Chairman and CEO Brent Saunders acknowledged their contributions over the past three years.
Bausch + Lomb (NYSE/TSX: BLCO), a global eye health company, has announced its participation in two upcoming investor conferences in September 2025. At the J.P. Morgan European Leveraged Finance Conference on September 3 in London, CFO Sam Eldessouky will conduct investor meetings.
Additionally, CEO Brent Saunders and CFO Sam Eldessouky will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on September 8 at 7:45 a.m. ET in New York. The Morgan Stanley presentation will be available via webcast on the company's Investor Relations website.
Bausch + Lomb (NYSE/TSX: BLCO) reported Q2 2025 financial results with total revenue of $1.278 billion, representing a 5% increase as reported and 3% growth on a constant currency basis compared to Q2 2024. The company posted a GAAP net loss of $62 million and Adjusted EBITDA of $191 million.
By segment, Vision Care revenue grew 8% to $753 million, Surgical increased 3% to $216 million, while Pharmaceuticals remained flat at $309 million. The company has raised its full-year 2025 guidance, now projecting revenue between $5.050B - $5.150B with 5-7% constant currency growth.
Notable achievements include reaching $1 billion in trailing 12-month revenue across the dry eye portfolio and resuming full production of enVista® platform IOLs following a market return.
Bausch + Lomb (NYSE/TSX: BLCO) has announced the publication of Phase 3 study results for its LUMIFY Preservative Free redness reliever eye drops in Ophthalmology and Therapy. The study, involving 380 participants, demonstrated that the preservative-free formulation is non-inferior to the original LUMIFY in reducing ocular redness.
The clinical trial showed the new formulation delivers results in one minute and lasts up to eight hours. The study met its primary objective, with participants receiving single drops four times daily for four weeks. Both formulations demonstrated comparable safety profiles and low incidence of side effects like rebound redness when used as directed.
Bausch + Lomb (NYSE/TSX: BLCO) has launched "Eyes Tell the Story: The Impact of Dry Eye," a campaign aimed at educating the public about dry eye through personal stories, imagery, and new survey data. The initiative builds upon their 2024 "Know Your Dry Eye" educational campaign.
The company's latest survey revealed significant findings: 78% of sufferers desire more resources and education on dry eye, 62% incorrectly assume dry eye resolves itself after treatment, and 40% waited six months or more before seeking medical help. The campaign features collaboration with photographer Kayte Demont, who captured portraits of dry eye sufferers including interior designer Alvin Wayne and lifestyle blogger Brianne Manz.
According to the company, approximately 150 million U.S. adults experience occasional or frequent dry eye symptoms, with 38 million living with chronic dry eye disease. The campaign emphasizes the importance of early intervention and highlights that relief options range from over-the-counter drops to prescription treatments.